June 10, 2020 / 11:10 AM / in 24 days

BRIEF-Fulcrum Therapeutics To Evaluate Losmapimod As Potential Treatment For Covid-19

June 10 (Reuters) - Fulcrum Therapeutics Inc:

* FULCRUM THERAPEUTICS TO EVALUATE LOSMAPIMOD AS POTENTIAL TREATMENT FOR COVID-19

* FULCRUM THERAPEUTICS - REDUX4 INTERIM ANALYSIS IN FACIOSCAPULOHUMERAL DYSTROPHY ON TRACK FOR Q3 READOUT

* FULCRUM THERAPEUTICS INC - FTX-6058 PHASE 1 TRIAL ON TRACK FOR Q4 2020 INITIATION

* FULCRUM THERAPEUTICS INC - INVESTIGATIONAL NEW DRUG APPLICATION SUBMITTED FOR LOSMAPIMOD

* FULCRUM THERAPEUTICS- PREPARING TO START PHASE 3 TRIAL FOR LOSMAPIMOD

* FULCRUM THERAPEUTICS - EXPECTS CASH, AS OF MARCH 31, TO BE SUFFICIENT TO FUND CAPEX NEEDS IN Q1 2022 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below